Neutrophil Neoantigens in Lupus: T- and B-Cell Recognition

Lupus is an autoimmune disease in which the immune system attacks the body’s own tissues. Its causes are complex and may include genetic susceptibility, immune dysregulation, environmental triggers, inflammation, and tissue damage.

New research suggests that abnormal RNA splicing in neutrophils may generate altered molecules recognized by both T cells and B cells in people with lupus. These molecules are known as neutrophil neoantigens. The finding may connect neutrophil abnormalities with the adaptive immune responses that sustain inflammation.

The research does not establish a diagnostic test or approved treatment. It offers a possible mechanism for lupus autoimmunity and raises questions about which neoantigens are involved, whether they occur in specific patient groups, and whether blocking their recognition could reduce disease activity.

What Are Neoantigens?

An antigen is a molecule or molecular fragment that the immune system can recognize. It may come from a virus, bacterium, damaged tissue, or the body’s own cells.

A neoantigen is a newly formed or altered antigen that differs from the body’s usual molecular targets. Neoantigens do not necessarily result from inherited genetic mutations. They can arise through changes in gene expression, protein processing, cellular mutations, or RNA splicing.

The immune system is generally trained to tolerate conventional self-antigens found in healthy tissues. Neoantigens may appear only during cellular stress, inflammation, abnormal cell death, or disease-related changes in protein production. Because these altered targets may not have been encountered during immune development, T cells or B cells may treat them as unusual or threatening.

The Neoantigen Hypothesis in Autoimmunity

The neoantigen hypothesis proposes that newly generated self-antigens can initiate or intensify autoimmune disease. A possible sequence is:

1. Cellular stress or a molecular alteration creates a new antigen.
2. Immune cells process or bind the altered material.
3. T cells and B cells recognize the target.
4. Inflammation develops or persists.
5. Further tissue damage releases additional immune-stimulating material.

This hypothesis does not explain every autoimmune disease or replace established models of lupus. Genetic risk, infections, hormonal factors, environmental exposures, defective immune regulation, and tissue injury may all contribute.

A review describes neoantigens as a possible bridge between disease-associated cellular changes and autoimmune responses, while emphasizing that the concept remains under investigation rather than serving as a complete disease model Source 7.

How Abnormal RNA Splicing May Create Neutrophil Neoantigens

Genes are transcribed into RNA before cells use that information to produce proteins. Initial RNA transcripts usually contain coding segments called exons and intervening noncoding segments called introns. During RNA splicing, introns are removed and exons are joined to form messenger RNA.

Cells can also use alternative splicing to combine RNA segments in different ways, allowing one gene to produce multiple protein forms. Accurate splicing helps determine a protein’s length, structure, location, and function.

Abnormal splicing can produce messenger RNA sequences that differ from the usual version. These changes may generate:

• Altered proteins.
• Shortened or extended protein products.
• Proteins with unusual structures.
• Proteins sent to the wrong cellular location.
• Peptides that are not normally displayed to immune cells.

Some of these products may become neoantigens. However, not every abnormal splicing event creates a disease-causing immune target. The altered product must be produced, processed, exposed to immune cells, and recognized strongly enough to trigger a response.

The reported study found that some splicing-derived products in neutrophils can be recognized by adaptive immune cells in lupus. This makes abnormal RNA splicing relevant to lupus research because it may explain how immune cells generate targets that were previously invisible to the immune system Source 1.

Why Neutrophils Matter

Neutrophils are abundant white blood cells that provide rapid defense against infection. They engulf harmful particles, release inflammatory mediators, and form neutrophil extracellular traps, or NETs, that can immobilize pathogens.

Neutrophils can also promote inflammation when excessively activated or when they die in ways that release intracellular material. In lupus, abnormal neutrophil activity and NET formation have been studied as possible sources of self-directed immune stimulation.

This environment could make splicing-derived proteins or peptides more visible to the immune system. Neutrophil damage may release altered material, while antigen-presenting cells process some of it and display fragments to T cells. B cells may bind related structures through their receptors and produce antibodies.

The findings identify immune recognition of neutrophil neoantigens. They do not prove that these neoantigens are the only cause of lupus or that the same process occurs in every patient.

T-Cell Recognition of Splicing-Derived Targets

T cells generally recognize short antigen fragments displayed by major histocompatibility complex molecules. Antigen-presenting cells process proteins into smaller peptides and display them on their surfaces. T cells inspect these fragments through their T-cell receptors.

When a T cell recognizes a relevant peptide in the correct inflammatory context, it may become activated. Activated T cells can produce signaling molecules, help B cells, recruit other immune cells, and intensify local inflammation.

The Nature study reported that T cells recognize neutrophil neoantigens generated through abnormal RNA splicing in lupus Source 1.

This result indicates that altered splicing products are not merely biochemical abnormalities. At least some become immunologically visible. It also provides a possible link between neutrophil dysfunction and adaptive immunity. T-cell responses may help maintain inflammation after the original cellular stress has changed.

The available summary does not identify the exact antigen sequences, T-cell subsets, or cytokines involved. Those details should not be assumed.

B-Cell Recognition and Antibody Responses

B cells recognize molecular structures through B-cell receptors. Unlike T cells, B cells can bind certain features on intact proteins or other molecular surfaces.

After activation, B cells may multiply, present antigen to T cells, form memory cells, or mature into plasma cells that produce antibodies. If B cells produce antibodies against splicing-derived neutrophil targets, those antibodies could potentially contribute to immune-complex formation or tissue inflammation.

That outcome depends on the target, antibody type, amount of released antigen, and how the immune system clears the resulting complexes. It remains a possible implication rather than a confirmed clinical consequence of the study summary.

Why Recognition by Both Cell Types Matters

A possible model is:

1. Abnormal RNA splicing causes a neutrophil to produce an unusual protein or peptide.
2. Neutrophil damage or cell death releases the altered material.
3. Antigen-presenting cells process relevant fragments and display them to T cells.
4. B cells bind related structures through their receptors.
5. Activated T cells provide signals that support B-cell proliferation and maturation.
6. B cells produce antibodies and establish immune memory.
7. Repeated neutrophil activation releases more target material.

This interaction could help explain how lupus becomes self-sustaining. Even if the original trigger disappears, immune memory and continuing tissue damage may preserve the response.

The model remains hypothetical as a complete disease sequence. The study supports recognition of neutrophil neoantigens, but further research must establish whether these responses initiate lupus, amplify established disease, or arise as a consequence of inflammation.

How Neutrophil Abnormalities May Contribute to Lupus

A cautious framework involves several connected events:

1. Disease-associated stress alters RNA splicing in neutrophils.
2. Neutrophils produce unusual proteins or peptides.
3. Neutrophil death, damage, or NET formation releases those products.
4. Antigen-presenting cells display relevant fragments to T cells.
5. B cells recognize associated structures and produce antibodies.
6. T-cell and B-cell activity promotes inflammation.
7. Tissue injury releases additional self-material and sustains the cycle.

This framework connects innate immune abnormalities with adaptive immune activation. It also explains why neutrophils may matter even though lupus is often discussed through its antibodies and affected organs.

The cycle is not confirmed in every patient. Lupus is heterogeneous, so different patients may have different dominant mechanisms involving antibodies, interferon signaling, complement activation, kidney inflammation, or other pathways.

Mutations and splicing abnormalities are not the same process. Mutations alter the genetic sequence itself, whereas splicing abnormalities alter how RNA instructions are assembled after transcription. Both can potentially produce altered proteins, but evidence of one does not prove the other. Available summaries do not support the conclusion that mutations in neutrophils directly cause lupus Source 3.

Why These Findings Could Change Lupus Research

Potential Biomarkers

Future studies could investigate whether splicing-derived neutrophil targets become useful biomarkers by:

• Detecting abnormal splicing products in neutrophils.
• Measuring T-cell responses to selected neoantigens.
• Testing for antibodies against splicing-derived targets.
• Comparing lupus patients with healthy controls and people with other autoimmune diseases.
• Examining whether responses change during flares or treatment.

A clinically useful biomarker would need to be specific, reproducible, and associated with disease activity, organ involvement, prognosis, or treatment response. Current findings do not establish such a test.

Potential Treatments

If particular neutrophil neoantigens prove to be disease-relevant, researchers could investigate:

• Blocking presentation of selected antigen fragments.
• Reducing abnormal neutrophil activation or survival.
• Interrupting T-cell and B-cell communication.
• Targeting antibodies directed at disease-associated structures.
• Limiting harmful NET formation.
• Correcting or reducing abnormal RNA-splicing events.

These approaches remain investigational. Broad suppression of neutrophils, T cells, or B cells could weaken protection against infection. Disease-specific targets might reduce collateral immune suppression, but that possibility requires substantial validation.

Limits of the Evidence

The Nature report supports the claim that T cells and B cells recognize neutrophil neoantigens associated with abnormal RNA splicing in lupus Source 1.

The Frontiers review supports the broader concept that newly generated self-antigens may contribute to autoimmune responses Source 7.

The available summaries do not establish:

• The exact neoantigen sequences.
• The number and characteristics of participants.
• Whether all patients with lupus produce these responses.
• How responses compare with healthy controls or other autoimmune diseases.
• Whether recognition predicts flares or organ damage.
• Whether abnormal splicing precedes disease activity.
• Whether blocking the response improves lupus.
• Whether any treatment based on these findings is clinically available.

The findings should not be described as proof that neutrophil neoantigens cause lupus in every patient. They also do not establish a current diagnostic test or therapeutic breakthrough.

What Researchers May Study Next

Researchers can identify the specific proteins or peptides generated by abnormal neutrophil splicing and determine whether the same targets occur across independent lupus cohorts. Comparisons with healthy people and patients with other autoimmune diseases will help establish specificity.

Further work can test whether responses correlate with disease activity, kidney or other organ involvement, flares, treatment response, antibody profiles, disease duration, or particular lupus subtypes.

Cellular and animal models can examine whether exposure to specific neoantigens initiates or worsens autoimmunity. Researchers can also test whether blocking antigen presentation, T-cell activation, or B-cell responses reduces inflammation.

Timing is another key question. Abnormal splicing may occur before a flare and help drive it, or it may arise after inflammation has already begun. Distinguishing cause from consequence will determine the mechanism’s therapeutic importance.

Conclusion

The central finding is that T cells and B cells can recognize neutrophil neoantigens produced through abnormal RNA splicing in lupus. This provides a possible bridge between neutrophil dysfunction and adaptive immune activation.

The result supports a broader model in which disease-related changes inside immune cells create altered self-components. These components may activate T cells, support B-cell antibody production, and help sustain inflammation. The model may explain part of lupus biology, but it does not replace other mechanisms or necessarily apply to every patient.

Future research must identify the relevant neoantigens, establish how common the responses are, connect them with clinical features, and test whether targeting them improves disease. Understanding how disease-specific immune targets arise could eventually support more precise lupus diagnosis and treatment.

Frequently Asked Questions

What are neutrophil neoantigens in lupus?

They are altered molecules or protein fragments produced by neutrophils that may appear unusual to the immune system. In the reported study, some were generated through abnormal RNA splicing and recognized by T cells and B cells in lupus.

How can abnormal RNA splicing create an autoimmune target?

RNA splicing determines how genetic instructions are assembled into messenger RNA. Abnormal splicing can produce unusual proteins or fragments. If immune cells encounter and recognize those products, they may become neoantigens.

What is the difference between T-cell and B-cell recognition?

T cells generally recognize processed antigen fragments displayed by other cells. B cells recognize molecular structures through B-cell receptors and can produce antibodies after activation. Recognition by both cell types suggests the potential for coordinated adaptive immune responses.

Do neutrophil neoantigens cause lupus?

The findings suggest that they may contribute to lupus-related immune responses, but they do not prove that they cause lupus in every patient. Lupus likely results from interactions among genetic susceptibility, immune dysregulation, environmental factors, and tissue damage.

Could these neoantigens become a lupus diagnostic test?

They may become research targets for future biomarkers. No diagnostic test can be inferred from the available findings. Researchers must establish whether responses are specific, reproducible, and associated with disease activity or treatment response.

Could future lupus treatments target these neoantigens?

Possible strategies include blocking neoantigen presentation, reducing harmful neutrophil activity, or interrupting T-cell and B-cell responses. These approaches remain investigational and require evidence that they improve lupus without weakening essential immune defense.